Literature DB >> 18766957

Intrathecal liposomal cytarabine: more friend than foe?

Deepa Bhojwani1, Ching-Hon Pui.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18766957      PMCID： PMC2803076          DOI： 10.1080/10428190802220527

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  14 in total

1.  Results of compassionate therapy with intrathecal depot liposomal cytarabine in acute myeloid leukemia meningeosis.

Authors:  Juan-Manuel Sancho; Guillermo Deben; Anne Parker; José-Luis Piñana; Simon Bolam; Eva Sánchez-García; Eugenio Giménez; Teresa Pascual; Pascual Fernández-Abellán; Luis Palomera; Josep-Maria Ribera
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

2.  Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia.

Authors:  Elias Jabbour; Susan O'Brien; Hagop Kantarjian; Guillermo Garcia-Manero; Alessandra Ferrajoli; Farhad Ravandi; Maria Cabanillas; Deborah A Thomas
Journal:  Blood       Date:  2007-01-05       Impact factor: 22.113

3.  Compassionate use of intrathecal depot liposomal cytarabine as treatment of central nervous system involvement in acute leukemia: report of 6 cases.

Authors:  Juan-Manuel Sancho; Josep-Maria Ribera; Maria-José Romero; Victoria Martín-Reina; Pilar Giraldo; Elena Ruiz
Journal:  Haematologica       Date:  2006-03       Impact factor: 9.941

4.  Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis.

Authors:  M J Glantz; S LaFollette; K A Jaeckle; W Shapiro; L Swinnen; J R Rozental; S Phuphanich; L R Rogers; J C Gutheil; T Batchelor; D Lyter; M Chamberlain; B L Maria; C Schiffer; R Bashir; D Thomas; W Cowens; S B Howell
Journal:  J Clin Oncol       Date:  1999-10       Impact factor: 44.544

5.  A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.

Authors:  M J Glantz; K A Jaeckle; M C Chamberlain; S Phuphanich; L Recht; L J Swinnen; B Maria; S LaFollette; G B Schumann; B F Cole; S B Howell
Journal:  Clin Cancer Res       Date:  1999-11       Impact factor: 12.531

6.  Extended CSF cytarabine exposure following intrathecal administration of DTC 101.

Authors:  S Kim; E Chatelut; J C Kim; S B Howell; C Cates; P A Kormanik; M C Chamberlain
Journal:  J Clin Oncol       Date:  1993-11       Impact factor: 44.544

7.  Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis.

Authors:  L Bomgaars; J R Geyer; J Franklin; G Dahl; J Park; N J Winick; R Klenke; S L Berg; S M Blaney
Journal:  J Clin Oncol       Date:  2004-10-01       Impact factor: 44.544

8.  Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases.

Authors:  M C Chamberlain; P Kormanik; S B Howell; S Kim
Journal:  Arch Neurol       Date:  1995-09

9.  Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis.

Authors:  Martin Benesch; Petra Sovinz; Barbara Krammer; Herwig Lackner; Georg Mann; Wolfgang Schwinger; Helmut Gadner; Christian Urban
Journal:  J Pediatr Hematol Oncol       Date:  2007-04       Impact factor: 1.289

10.  Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine.

Authors:  K A Jaeckle; S Phuphanich; M J Bent; R Aiken; T Batchelor; T Campbell; D Fulton; M Gilbert; D Heros; L Rogers; S J O'Day; W Akerley; J Allen; S Baidas; S Z Gertler; H S Greenberg; S LaFollette; G Lesser; W Mason; L Recht; E Wong; M C Chamberlain; A Cohn; M J Glantz; J C Gutheil; B Maria; P Moots; P New; C Russell; W Shapiro; L Swinnen; S B Howell
Journal:  Br J Cancer       Date:  2001-01       Impact factor: 7.640
View more
  7 in total

Review 1.  Central nervous system disease in hematologic malignancies: historical perspective and practical applications.

Authors:  Ching-Hon Pui; Eckhard Thiel
Journal:  Semin Oncol       Date:  2009-08       Impact factor: 4.929

2.  Intrathecal liposomal cytarabine in children under 4 years with malignant brain tumors.

Authors:  Alvaro Lassaletta; Blanca Lopez-Ibor; Elena Mateos; Marta Gonzalez-Vicent; Antonio Perez-Martinez; Julian Sevilla; Miguel A Diaz; Luis Madero
Journal:  J Neurooncol       Date:  2009-04-18       Impact factor: 4.130

Review 3.  Intrathecal drug delivery in the era of nanomedicine.

Authors:  M J Fowler; J D Cotter; B E Knight; E M Sevick-Muraca; D I Sandberg; R W Sirianni
Journal:  Adv Drug Deliv Rev       Date:  2020-03-03       Impact factor: 15.470

Review 4.  Implications of Intrathecal Chemotherapy for Anaesthesiologists: A Brief Review.

Authors:  Abhijit Nair
Journal:  Scientifica (Cairo)       Date:  2016-03-31

5.  Analysis of the role of intratecal liposomal cytarabine in the prophylaxis and treatment of central nervous system lymphomatosis: The Balearic Lymphoma Group experience.

Authors:  Marta García-Recio; Antonia Cladera; Leyre Bento; Julia Dominguez; Silvia Ruiz de Gracia; Francesca Sartori; Raquel Del Campo; Lucia García; Carmen Ballester; Jordi Gines; Joan Bargay; Antonia Sampol; Antonio Gutiérrez
Journal:  PLoS One       Date:  2017-06-30       Impact factor: 3.240

Review 6.  Liposomal Cytarabine as Cancer Therapy: From Chemistry to Medicine.

Authors:  Bahare Salehi; Zeliha Selamoglu; Ksenija S Mileski; Raffaele Pezzani; Marco Redaelli; William C Cho; Farzad Kobarfard; Sadegh Rajabi; Miquel Martorell; Pradeep Kumar; Natália Martins; Tuhin Subhra Santra; Javad Sharifi-Rad
Journal:  Biomolecules       Date:  2019-11-23

Review 7.  Using the Promise of Sonodynamic Therapy in the Clinical Setting against Disseminated Cancers.

Authors:  Matthew Trendowski
Journal:  Chemother Res Pract       Date:  2015-08-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.